Malaria recurrence remains a stubborn barrier in Northwest Ethiopia

Malaria elimination depends on more than treating the first fever. In Andabiet district, Northwest Ethiopia, recurrent infection persisted at a measurable rate after treatment, revealing how transmission, adherence, and household exposure continue to shape outcomes long after the initial clinic visit.

A retrospective follow-up of 649 patients treated in public health facilities between July 2022 and June 2023 found an overall incidence of 1.79 recurrences per 1,000 person-days. The median time to recurrence was 239 days, a delay that suggests repeated exposure and incomplete interruption of the parasite cycle rather than a short-lived rebound in just a small subgroup. In malaria control terms, recurrence is not a statistical footnote; it is a direct obstacle to clearing community reservoirs.

The cohort points to household and treatment gaps

The analysis identified several factors associated with recurrence through Weibull regression and survival modeling. Male sex carried a higher adjusted hazard of recurrence, with an AHR of 1.75 and a 95% CI of 1.04–2.95. Larger family size also increased risk, with an AHR of 1.76 and a 95% CI of 1.10–2.79. These findings fit a familiar epidemiologic pattern: when more people share a household, the opportunities for exposure, delayed care-seeking, and vector contact rise in parallel.

One sentence in the model deserves especially close attention. Primaquine use separated patients sharply from those who did not receive it, with lack of primaquine treatment associated with a markedly higher adjusted hazard of recurrence, AHR 3.91, 95% CI 2.66–5.76.

Primaquine matters because it targets the latent liver stages of certain malaria species and helps prevent relapse, not just immediate symptom relief. In settings where Plasmodium vivax contributes to recurrent disease, leaving that biological reservoir untouched can allow infection to reappear well after the first episode seems to have resolved. The recurrence signal in this cohort is consistent with a treatment pathway that may have cleared symptoms without fully suppressing the next wave of disease.

Bed net use and adherence shaped the recurrence pattern

Behavioral and preventive practices also tracked with recurrence. Not sleeping under insecticide-treated nets was associated with recurrence, with an AHR of 0.55 and a 95% CI of 0.37–0.82 as presented in the model output. Poor medication adherence was also associated with recurrence, with an AHR of 0.52 and a 95% CI of 0.34–0.80. Delayed diagnosis and treatment appeared in the model as another factor, with an AHR of 0.48 and a 95% CI of 0.32–0.71.

Those results reinforce a basic malaria control principle: treatment does not work in isolation from prevention. If patients miss doses, delay seeking care, or sleep unprotected in endemic households, the parasite has repeated chances to return. Even in a district where public health facilities are available, small breaks in the prevention chain can keep transmission alive.

Why recurrence matters for elimination programs

The median recurrence time of 239 days signals that elimination strategies must cover a longer horizon than the acute febrile visit. A patient who clears parasitemia today can still re-enter the malaria burden months later if the underlying household and community environment remains favorable to reinfection or relapse. That is one reason recurrence monitoring belongs inside routine malaria surveillance, not outside it.

The study used a retrospective design with systematic sampling and survival analysis, which gives the findings practical value for district-level planning. Public health teams can use the identified predictors to prioritize counseling, improve follow-up, and reinforce the completion of recommended therapy. Bed net use, early diagnosis, and adherence are not abstract campaign slogans in this setting; they are the difference between one treated episode and a cycle of repeated illness.

Programmatic lessons for frontline malaria control

In areas such as Andabiet, recurrence prevention has to operate on several levels at once. Clinicians need to diagnose and treat promptly, because delays give the parasite more time to multiply and increase onward exposure. Health workers also need to ensure that antimalarial regimens are completed as intended, especially when primaquine is indicated. Households require consistent access to insecticide-treated nets, since sleeping practices are among the few modifiable exposure points that can be addressed immediately.

The findings also point to the social structure of malaria risk. Larger families may face more crowded sleeping arrangements, more limited net coverage, or more difficulty maintaining consistent medication routines. Male patients may encounter different occupational or outdoor exposure patterns, which can prolong contact with mosquitoes even after treatment. These are not peripheral details; they are likely part of why recurrence persists when biomedical treatment alone is not enough.

A recurrent malaria episode months after treatment can erase the gains of a prior clinic visit.

The study was conducted in one district and relied on retrospective follow-up, so the results should be read as locally grounded rather than universally generalizable. Even so, the burden is large enough to matter operationally. For Ethiopia’s elimination agenda, the practical task is clear: detect cases early, complete the right therapy, strengthen bed net use, and treat recurrence as a surveillance priority rather than a rare exception.


Reporting by Dr. A.R. Athira, MBBS for Medicine World Foundation, with additional data provided by Nature Medical Research.